Table 2.
Measures of glycaemic control and body composition at baseline and 6 months after stroke.
| Baseline | Six months | Effect size (95% CI)a,b Change per month | p a | |
|---|---|---|---|---|
| Oral glucose tolerance test (OGTT) | ||||
| 2-h glucose (mmol/L) | 7.9 (6.7, 10.3), n = 24 | 5.9 (4.6, 7.7), n = 26 | 0.96 (0.94, 0.97) | <0.001 |
| Glucose responsec, N (%) | n = 23 | n = 26 | n/a | 0.033 |
| Normal | 12 (52.2) | 20 (76.9) | ||
| Impaired | 6 (26.1) | 6 (23.1) | ||
| Diabetic | 5 (21.7) | 0 | ||
| HOMA2 %S | 75.9 (50.5, 102.1), n = 30 | 92.2 (72.8,160.9), n = 29 | 1.03 (1.002, 1.06) | 0.04 |
| HbA1c | n = 31 | n = 29 | 0.18 | |
| mmol/mol | 40 (38, 41) | 41 (39, 42) | 1.001 (0.99, 1.02) | |
| % | 5.8 (5.6, 5.9) | 5.9 (5.7, 6.0) | ||
| HOMA2 %B | 115.7 (80.2, 136.4), n = 30 | 107.6 (86.5, 148.8), n = 29 | 2.51 (0.15, 41.89) | 0.52 |
| C-peptide | 1.04 (0.9, 1.32), n = 29 | 0.82 (0.67 1.06), n = 28 | 0.99 (0.95, 1.04) | 0.92 |
| Fat mass (kg) | 23.5 (16.5, 33.1), n = 28 | 20.9 (14.7, 27.9), n = 27 | 0.98 (0.97, 0.99) | 0.01 |
| Lean mass (kg) | 47.2 (40.8, 53.1), n = 28 | 49.1 (41.2, 54.8), n = 27 | 1.001 (0.999, 1.003) | 0.35 |
| Waist/hip ratio | 0.96 (0.86, 1.03), n = 24 | 0.93 (0.84, 1.01), n = 28 | 0.99 (0.98, 1.003) | 0.15 |
| Body mass index (kg/m2) | 26.5 (23.1, 30.3), n = 32 | 25.1 (22.9, 27.1), n = 26 | 0.82 (0.58, 1.16) | 0.26 |
Note. Data are presented median (IQR) unless otherwise specified.
a
GEE: generalised estimating equation; HbA1c: glycated haemoglobin A1c; HOMA2: updated Homeostasis Model Assessment; HOMA2 %S: insulin sensitivity; HOMA2 %B: beta cell function.
b
Adjusted for age and stroke severity (National Institute of Health Stroke Scale, NIHSS).
c
Normal fasting = <5.6 mmol/L; impaired glucose tolerance (IGT) = 2-h glucose 7.8–11.1 mmol/l; diabetes = 2-h glucose ≥ 11.1 mmol/l.19